The FDA has approved UCB’s Keppra (levetiracetam) injection for use as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. Keppra injection is an alternative for patients when oral administration is temporarily not feasible.
Product news from the 08/08/06 News Brief
The FDA has approved UCB’s Keppra (levetiracetam) injection for use as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy.
